What is retatrutide? | Retatrutide weight-loss injections

Retatrutide is a triple-action weight-loss injection manufactured by Eli Lilly. It’s undergoing later-stage human clinical trials to determine its effectiveness across a broader population.

Retatrutide is known as a ‘triple hormone receptor agonist’. This means it mimics the actions of three hormones in the body that directly affect our ability to control hunger and our blood sugar levels.

Retatrutide is likely going to be approved for individuals living with obesity and type 2 diabetes, should it receive approval from the MHRA in the UK and the FDA in the U.S.

The three hormones that retatrutide mimics are:

1. GLP-1: Lowers appetite and blood sugar levels
2. GIP: Lowers appetite and blood sugar levels
3. Glucagon: Promotes fat breakdown for energy use and prevents low blood sugar levels

The triple action of retatrutide means it has a profound effect on appetite and the management of blood sugar levels and is expected to be more effective than semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) for weight loss.